THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER
https://doi.org/10.24060/2076-3093-2013-0-3-28-34
Abstract
The role of the level of prostate specific antigen ( PSA) before initial therapy discusses widely as a prognostic factor in the treatment of prostate cancer (PC ). Despite the fact that many of the questions on the diagnostic and prognostic value of PSA unclear, and new markers of prostate diseases are being introduced with increasing frequency , we assume that the PSA will continue to be one of the main methods of screening and monitoring of patients with prostate cancer, because of its high diagnostic value due to tissue specificity. Using the initial PSA level and Gleason score improves the predictive value significantly. This article presents the results of a retrospective analysis of 307 patients completed the treatment of PC. The effect of baseline PSA level and Gleason score on the choice of treatment , the effectiveness of hormone deprivation and overall survival are evaluated.
About the Authors
A. A. Gritskevich
Clinical Oncology Department №1
Russian Federation
Krasnodar
Russian Federation
Krasnodar
V. L. Medvedev
Prof. S.V. Ochapovsky’s Regional Clinical Hospital № 1
Russian Federation
Krasnodar
Russian Federation
Krasnodar
S. V. Mishugin
City Clinical Hospital № 57
Russian Federation
Russian Federation
Moscow
N. A. Apolskaya
City polyclinic № 218
Russian Federation
Russian Federation
Moscow
I. G. Rusakov
City Clinical Hospital № 57
Russian Federation
Russian Federation
Moscow
References
1. Чехонин В.П., Григорьев М.Э., Жирков Ю.А.Простатический специфический мембранный антиген и его роль в диагностике рака предстательной железы // Вопросы медицинской химии. – 2002. – № 48. С. 31-43.
2. Чиссов В.И., Старинский В.В., Петрова В. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). – М., 2013.
3. Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004 // Ann Oncol. – 2005. – Mar. – Vol. 16(3). –P. 481-488.
4. Brawn P.N., Speights V.O., Kuhl D. et. al. Prostate specific antigen levels from completely sectioned, clinically benign, whole prostates // Cancer. – 1991. – Vol. 68. – P. 1592-1599.
5. Breul. J., Pickl U., Hartung Prostate-specific antigen in urine // Eur. Urol. 1994. Vol. 26. – Suppl. 1. P. 18-21.
6. Carter H.B., Pearson J.D., Metter E.J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease // JAMA. 1992ю Vol. 267. P. 2215-2220.
7. Catalona W.J., Smith. D.S., Ornstein D.K. Prostate cancer detection in with serum PSA concentration of 2.6 to 4.0 ng/ml and benign prostate examination: Enhancement of specificity with free PSA measurements. J.A.M.A. 1997. Vol. 277. P. 1452-1455.
8. Collette L., de Reijke T.M., Schroder F.H. Prostate Specific Antigen: A Prognostic Marker of Survival in Good Prognosis Metastatic Prostate Cancer? (EORTC 30892) // Eur Uro. – 2003. Vol. 44. – P. 182-189.
9. Gleave M.E., Sato N., Goldenberg S.L., Stothers L. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tu¬mour excision in the shionogi tumour model. J Urol. – 1997. – Vol. 157. – P. 1727-1730.
10. Goeman L., Joniau S., Ponette D. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer? // Prostate Cancer and Prostatic Diseases. – 2003. – Vol. 6. P.305-310.
11. Jemal A., Siegel R., Ward E. et. al. Cancer statistics, 2008 // CA Cancer J Clin. 2008. Mar. – Vol. 58(2). – P. 71-96.
12. Morote-Robles J., Ruibal-Morell A., Palou-Redorta J., et. al. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: A comparative study // Eur Urol. 1988. – Vol. 14. – P. 360-366.
Review
For citations:
Gritskevich A.A., Medvedev V.L., Mishugin S.V., Apolskaya N.A., Rusakov I.G. THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER. Creative surgery and oncology. 2013;(3):28-34. (In Russ.) https://doi.org/10.24060/2076-3093-2013-0-3-28-34
Views:
633
Email this article 